The industry might agree to savings in 2020 to bolster those negotiated in 2017, only to confront a new round of requests in 2022 or 2023. Any extension in 2020 will mean the industry just pays again for the 'certainty' it already has until mid-2022. …
The price of paying twice or three times for the same 'certainty'
September 14, 2020 CommentLatest News
Latest Video
New Stories
-
AstraZeneca confirms pricing the issue, and acts to create a patient access program
June 16, 2026 - - Latest News -
When good policy becomes self defeating, Australia must at least have a discussion about the obvious solution
June 16, 2026 - - Latest News -
Entropy Neurodynamics clears safety hurdle for IV psilocin trial in binge eating disorder
June 15, 2026 - - Australian Biotech -
Paradigm reaches global milestone as Phase 3 osteoarthritis trial completes enrolment
June 15, 2026 - - Australian Biotech -
The 'Dispatched' Week in Review'- 14 June
June 15, 2026 - - Podcast -
Approach policy and pricing negotiations like planning for a product launch
June 15, 2026 - - Latest News -
High Court to decide on patent‑term extensions for formulations as GBMA intervenes
June 15, 2026 - - Latest News